 The Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA adopted a positive opinion recommending approval for ObsEva SAs NASDAQ: OBSV linzagolix, an oral GnRH antagonist to manage moderate to severe symptoms of uterine fibroids. If approved, linzagolix would be the first and only approved GnRH receptor antagonist with a non-hormonal option to address the needs of women who cannot or do not want to take hormones. 